What Trauma Taught Me That Medical School Never Did

Aug 18, 2026 | News

Image Source: Generated using Google Gemini
Independent Contributor
Written by: Michael J. Meighen, MD, Medical Director
On behalf of: Reboot Vitality

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body.

Like many physicians, I was trained to think of trauma primarily as a psychological injury, something best addressed through therapy, medication, or psychiatric care. Those treatments remain critically important, and I continue to believe trauma-focused psychotherapy is foundational to recovery. But after more than 26 years caring for veterans, first responders, healthcare professionals, executives, and patients living with chronic stress, I’ve come to believe we miss something essential when we view trauma through only a psychological lens.

Trauma also has a physiological dimension, a realization that has fundamentally changed how I practice medicine. Today, when someone walks into my office describing chronic anxiety, insomnia, hypervigilance, persistent pain, fatigue, or brain fog, I no longer see a collection of unrelated symptoms. I see a nervous system that may have spent months, or years, operating as though danger never ended.

The body is doing exactly what it was designed to do. The problem is that it never received the signal that it was finally safe to stop.

When Survival Becomes the Default

The autonomic nervous system exists to keep us alive. When we encounter a threat, the sympathetic nervous system rapidly mobilizes the body to respond: heart rate increases, blood pressure rises, stress hormones surge, muscles tense, and attention narrows. It’s an extraordinary survival mechanism.

In healthy circumstances, the parasympathetic nervous system restores equilibrium once the threat has passed. Heart rate slows, cortisol declines, digestion resumes, sleep becomes restorative, and the body shifts back into recovery mode. Trauma changes that equation.

Research over the past several decades has demonstrated that chronic or repeated traumatic stress can dysregulate the autonomic nervous system, alter the hypothalamic-pituitary-adrenal (HPA) axis, and produce persistent changes in inflammatory pathways, immune function, cardiovascular regulation, and pain processing. Rather than responding appropriately to danger, the nervous system begins anticipating it, even in objectively safe environments.¹–³

This helps explain why trauma rarely stays confined to emotional health.

Patients may develop chronic insomnia, gastrointestinal disturbances, headaches, muscle tension, chronic pain, fatigue, difficulty concentrating, heightened startle responses, or persistent feelings of being “on edge.” These symptoms often appear disconnected, but they’re frequently expressions of the same underlying physiological dysregulation.

When viewed through this lens, many behaviors that once seemed puzzling become understandable. The body isn’t malfunctioning. It’s protecting itself.

A Different Clinical Question

Early in my career, I often focused on treating individual symptoms.

How do we improve sleep?

How do we reduce anxiety?

How do we help this patient’s pain?

Those remain important questions. But increasingly, I’ve found myself asking something different:

How do we help this nervous system recover?

That shift changes treatment planning entirely. Instead of searching for a single intervention, recovery becomes an effort to restore physiologic balance across multiple interconnected systems. There is no single treatment that accomplishes that. Anyone suggesting otherwise is oversimplifying an extraordinarily complex condition.

Instead, recovery is often convergent: multiple evidence-based therapies working together to move the nervous system toward regulation.

Recovery Is Multifaceted

Trauma-focused psychotherapy remains the cornerstone of treatment. Approaches such as cognitive behavioral therapy (CBT), cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR) have consistently demonstrated benefit for many patients with post-traumatic stress disorder and remain first-line recommendations in major clinical guidelines.⁴

These therapies accomplish something a procedure cannot: they help patients process traumatic experiences rather than addressing only the body’s physiological response.

At the same time, successful therapy often depends on whether the nervous system is regulated enough to tolerate that work. Patients who remain in a constant state of hyperarousal may struggle to fully engage in psychotherapy, underscoring the importance of supporting the body’s physiology alongside psychological treatment.

Exercise is another intervention whose effects extend far beyond physical fitness.

When appropriately prescribed, graded aerobic exercise has been shown to improve autonomic function, reduce systemic inflammation, enhance sleep quality, and improve mood. Importantly, exercise should not be prescribed simply as “work out more.” For individuals with significant autonomic dysregulation, overly intense activity may initially feel threatening rather than restorative. Like any medical intervention, exercise benefits from thoughtful dosing and progression.⁵

Sleep deserves equal attention. Sleep is when the nervous system performs much of its restorative work, yet chronic sympathetic activation often makes restorative sleep nearly impossible. Patients frequently describe waking repeatedly throughout the night, remaining hypervigilant even while exhausted, or feeling as though their body never truly relaxes. Improving sleep through behavioral interventions, circadian regulation, and treatment of underlying physiological contributors often creates meaningful improvement across multiple symptom domains.⁶

Even relatively simple interventions, including breathing retraining, mindfulness practices, and nutrition, can contribute meaningfully to recovery.

Controlled breathing represents one of the few voluntary mechanisms individuals have to directly influence autonomic function. Slow diaphragmatic breathing has been associated with increased parasympathetic activity and improved heart rate variability, offering patients a practical tool for regulating stress outside the clinical setting.⁷

Each intervention may appear modest in isolation. Together, they begin moving the nervous system toward balance.

Emerging Tools Within a Broader Framework

Among the newer interventions receiving increased attention is the stellate ganglion block (SGB). Although SGB has been used for decades in pain medicine, researchers have recently begun investigating whether temporarily interrupting excessive sympathetic nervous system signaling might help reduce symptoms of post-traumatic stress disorder in selected patients.

The concept is physiologically compelling: if the sympathetic nervous system has become persistently overactive, temporarily reducing that output may help create conditions in which the nervous system can move toward a healthier baseline.

The existing evidence is encouraging but appropriately cautious. A randomized, sham-controlled clinical trial published in JAMA Psychiatry found that two stellate ganglion block procedures produced significantly greater reductions in PTSD symptom severity over eight weeks compared with sham treatment among active-duty service members.⁸ Subsequent reviews have similarly concluded that while SGB appears promising as an adjunctive therapy, additional high-quality research is needed to better define which patients are most likely to benefit and how it should be integrated into comprehensive trauma care.⁹ That distinction matters. SGB is not a cure for PTSD, nor should it replace psychotherapy, rehabilitation, lifestyle interventions, or comprehensive medical care.

Rather, it represents one example of a broader shift occurring across trauma medicine, a growing recognition that addressing the physiology of trauma may help patients engage more fully in the psychological and behavioral work that long-term recovery requires.

Looking Ahead

If there’s one lesson trauma has taught me that medical school did not, it’s that the mind and body cannot be separated nearly as cleanly as we once believed. Trauma is rarely confined to thoughts or emotions. It leaves measurable effects throughout the nervous system and can influence many aspects of human physiology, from sleep and inflammation to pain perception, metabolism, cardiovascular health, and immune function.

The future of trauma medicine will likely draw from multiple disciplines: neuroscience, behavioral health, rehabilitation medicine, precision diagnostics, interventional procedures, and emerging technologies that help us better understand nervous system function.

No single treatment will define that future. Integration will. When patients ask me whether meaningful recovery is possible, my answer is yes—but not because we’ve discovered a miracle cure. It’s because we’re finally beginning to understand what trauma truly is. Not simply a psychological injury. A whole-body physiological condition that deserves whole-person care.

 

Author Bio

    Dr. Michael J. Meighen is Medical Director of Reboot Vitality and a board-certified physician in Physical Medicine and Rehabilitation and Pain Medicine with more than 26 years of clinical experience. He earned his medical degree from the University of Cincinnati and completed his residency at Charlotte Rehabilitation Hospital and a fellowship in Interventional Pain Medicine and Sports Medicine at the University of Florida. Dr. Meighen specializes in regenerative orthopedics, interventional pain management, nervous system reset therapies, hormone optimization, and longevity medicine, including his work using Dual Stellate Ganglion Blocks to help patients recovering from PTSD, anxiety, and burnout. He has a special interest in helping military personnel and veterans overcome PTSD, traumatic brain injury, and combat-related stress, and believes healthcare should be proactive, personalized, and focused on addressing root causes rather than symptoms.
    References:
    1. McEwen BS. Protective and Damaging Effects of Stress Mediators. New England Journal of Medicine. 1998;338(3):171 to 179. doi:10.1056/NEJM199801153380307
    2. Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. Nature Reviews Disease Primers. 2015;1:15057. doi:10.1038/nrdp.2015.57
    3. Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychological Bulletin. 2007;133(5):725 to 746. doi:10.1037/0033-2909.133.5.725
    4. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington DC: Department of Veterans Affairs, Department of Defense; 2023.
    5. Rosenbaum S, Vancampfort D, Steel Z, et al. Physical activity in the treatment of post-traumatic stress disorder: A systematic review and meta-analysis. Psychiatry Research. 2015;230(2):130 to 136. doi:10.1016/j.psychres.2015.10.017
    6. Germain A. Sleep disturbances as the hallmark of PTSD: where are we now? American Journal of Psychiatry. 2013;170(4):372 to 382. doi:10.1176/appi.ajp.2012.12040432
    7. Zaccaro A, Piarulli A, Laurino M, et al. How Breath-Control Can Change Your Life: A Systematic Review on Psycho-Physiological Correlates of Slow Breathing. Frontiers in Human Neuroscience. 2018;12:353. doi:10.3389/fnhum.2018.00353
    8. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(2):130 to 138. doi:10.1001/jamapsychiatry.2019.3474
    9. Yang Y, Pu R, Zhang D, et al. Stellate ganglion blockade for the treatment of post-traumatic stress disorder: A systematic review and meta-analysis. Autonomic Neuroscience: Basic and Clinical. 2025;262:103360. doi:10.1016/j.autneu.2025.103360
    The author holds a commercial interest in a clinic that provides stellate ganglion block as a paid treatment and therefore has a financial interest in one of the therapies discussed in this article. All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions

    Articles that may be of interest

    Beyond Tolvaptan: The Next Generation of ADPKD Therapies

    Beyond Tolvaptan: The Next Generation of ADPKD Therapies

    Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

    read more
    Weekly News Roundup | 17 August 2026

    Weekly News Roundup | 17 August 2026

    Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

    read more
    Weekly News Roundup | 10 August 2026

    Weekly News Roundup | 10 August 2026

    Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...

    read more

    Articles that may be of interest

    Beyond Tolvaptan: The Next Generation of ADPKD Therapies

    Beyond Tolvaptan: The Next Generation of ADPKD Therapies

    Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

    read more
    Weekly News Roundup | 17 August 2026

    Weekly News Roundup | 17 August 2026

    Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

    read more
    Weekly News Roundup | 10 August 2026

    Weekly News Roundup | 10 August 2026

    Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...

    read more